Nonalcoholic fatty liver disease (NAFLD) is a common clinicopathological condition characterized by significant lipid deposition in the hepatocytes of the liver parenchyma. The clinicopathologic spectrum of NAFLD ranges from simple steatosis to nonalcoholic steatohepatitis (NASH). Associations between obesity, type 2 diabetes mellitus, and steatosis have long been recognized, as has the high prevalence of cirrhosis in diabetes. Although many treatment modalities have been used in patients with NASH, there is currently no proven effective treatment for NAFLD; however, a multimodal treatment plan that targets obesity, insulin resistance, hyperlipidemia, and hypertension might be the best option.